ROLR vs IVF
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 04, 2026
ROLR
35.0
AI Score
VS
ROLR Wins
IVF
29.2
AI Score
Investment Advisor Scores
IVF
29score
Recommendation
SELL
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | ROLR | IVF | Winner |
|---|---|---|---|
| Revenue | 6.17M | 1.64M | ROLR |
| Net Income | -4.33M | -17.40M | ROLR |
| Net Margin | -70.2% | -1063.0% | ROLR |
| Operating Income | -4.46M | -1.20M | IVF |
| ROE | -14.6% | 64.0% | IVF |
| ROA | -11.8% | -54.8% | ROLR |
| Total Assets | 36.74M | 31.74M | ROLR |
| Cash | 18.01M | 840,407 | ROLR |
| Current Ratio | 4.14 | 0.08 | ROLR |
| Free Cash Flow | -5.88M | -3.56M | IVF |
Relative Price Performance (Last 90 Days)
ROLR 1M: -32.9%
· 3M: -42.9%
IVF 1M: +355.1%
· 3M: +176.3%
Current Technical Phase
ROLR
MarkdownSell / avoid
Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 33
IVF
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (12.8% over 20 days), RSI 88
Fundamentals Snapshot
| Metric | ROLR | IVF |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -14.2 | -0.1 |
| Trailing P/E | — | 0.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.5% | 0.2% |
| Gross Margin | 0.6% | 0.4% |
| Operating Margin | -0.4% | -0.8% |
| EPS | -0.02 | 511.80 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, ROLR is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.